将投中网设为"星标⭐"，第一时间收获最新推送 投中信息第五年发布"投中榜·锐公司100榜单"，关注包括人工智能、机器人、低空经济、商业航天、 医疗健康等诸多科技创新赛道。 "2024投中榜·锐公司100"榜单，以上述领域的成长性企业在资本市 场的活跃度为基础，选出融资活跃度高、成长性强的企业，并以"锐"冠名之。锐即芒，从金而兑声， 自是锋芒毕露，生就勇往直前，于大千世界，森罗万象中。执着于理想，纯粹于当下，投中信息以资 本的视角观察科技创新的发展历程，让未来的轨迹更加触手可及。 本次榜单评选投中研究院从企业外部关注度、产业协同性以及产业影响力三大维度，综合进行报名征 集、问卷调研、市场挖掘、行业专家走访及数据分析等流程，综合评选出100家年度最具创新力和成 长力的创新科技企业。 根据问卷调研和CVSource投中数据统计，在本次入榜企业中， 约75%处于D轮前的融资阶段，表明 投资机构对于具有高增长潜力的创业企业给予了充分信任和支持。 值得注意的是， 部分企业甚至在 不到一年时间便完成了多轮融资 ，显示出资本市场的高度认可，反映出投资机构对于优质资产追逐 的热情，并为中国科技产业注入了源源不断的活力。北京、上 ...

Core Viewpoint - The article discusses the rapid development and commercialization of AI in the healthcare sector, particularly focusing on the impact of the DeepSeek model, which is reshaping the landscape of medical AI applications and investment opportunities [2][4][5]. Group 1: AI in Healthcare - The integration of AI in healthcare is not new, but the emergence of DeepSeek has reignited interest and investment in the sector, with over 30 companies in China embedding this technology into drug development, clinical decision-making, and chronic disease management [2][3]. - The stock performance of medical AI companies has been strong in various markets, with many stocks nearly doubling in value within a month [3][4]. - The long-term growth logic of the healthcare industry is becoming clearer, with predictions that AI will present significant investment opportunities in 2025 [4]. Group 2: DeepSeek's Impact - DeepSeek's low-cost and high-efficiency model significantly empowers the development of medical AI, reducing the costs associated with model training and inference by over 90% [9]. - The open-source strategy of DeepSeek allows healthcare companies to customize and optimize AI models for specific medical applications, enhancing the commercial viability of AI in healthcare [10][12]. - The ability to deploy DeepSeek locally addresses data privacy concerns, as sensitive medical data does not need to be uploaded to the cloud [12][13]. Group 3: Long-term Value and Applications - The core value of medical AI lies in its potential to provide accessible, precise, and sustainable healthcare services, especially in the context of an aging population and rising chronic diseases [15]. - AI can enhance the efficiency of various medical processes, including drug development, diagnostics, and patient management, thereby improving overall healthcare quality [16]. - Predictive AI is emerging as a significant area of focus, with the potential to assess future health risks and promote proactive healthcare measures [17]. Group 4: Data Challenges - The success of medical AI relies heavily on high-quality data, yet challenges remain regarding compliance, standardization, and data quality in the healthcare sector [18][19]. - The fragmentation of medical data across different institutions complicates the integration into comprehensive databases, posing significant technical and regulatory challenges [18]. Group 5: Investment Opportunities - The current market offers opportunities to identify companies with strong data and model capabilities, as well as those with established B2B customer bases in electronic medical records and clinical decision support [27]. - The year 2025 is anticipated to be a pivotal moment for the commercialization of medical AI, as the industry seeks transformative breakthroughs [27].

第一部分 Tempus Al近期股价强势且财务表现亮眼 01 "基因组学+数据服务+AI应用"业务模式形成飞轮效应 02 03 核心竞争力：广泛的多模态数据来源+Al赋能 国内为什么暂时没有自己的Tempus Al 04 05 对A股的投资启示 Tempus Al公司简介 · Tempus Al成立于2015年，此后专注于构建能够实时获取医疗数据以实现精准医疗的平台。公司的Tempus平台使得医生、诊断 公司、药企之间能够自由交换数据，打破了数据孤岛，有利于发掘数据的潜在价值，借助Al加快精准医疗的进步。 Tempus平台 最初聚焦于肿瘤领域, 此后逐渐拓展至心脏病、精神病等其他疾病领域。2024年6月公司在美国纳斯达克上市。 · 目前公司拥有三大产品线，分别为基因组学、数据服务、Al应用。基因组学产品线是通过自有实验室提供NGS诊断、基因分型等 诊断服务;数据服务业务是向药企提供去标识的诊断数据集和数据分析计算工具,或为药企提供临床试验患者匹配服务,提高药 物研发效率;AI应用业务是开发提供诊断算法,以此生成个性化诊断结果和优化治疗决策。 Tempus Al平台发展时间线 2017 Q1 2019.6 20 ...

一周IPO动态，覆盖港股、美股、A股。 本文为IPO早知道原创 作者｜C叔 微信公众号｜ipozaozhidao 毛戈平 港股｜挂牌上市 据IPO早知道消息，毛戈平化妆品股份有限公司（以下简称"毛戈平"）于2024年12月10日正式 以"1318"为股票代码在港交所主板挂牌上市，成为"港股国货高端美妆第一股"。 毛戈平在本次IPO中总计发行70,588,200股H股。其中，香港公开发售部分获919.18倍认购，国际 发售部分亦获30.34倍认购，累计认购总额超华润饮料时的认购规模、成为今年港股「冻资王」。 同时，毛戈平在本次IPO发行中共引入6名基石投资者，累计认购1亿美元。其中，CPE认购3500万 美元，正心谷资本认购2000万美元，ACCF Capital（由原L Catterton Asia合伙人王俊创办）认购 1500万美元，常春藤基金、Brilliant Partners Fund LP以及大湾区共同家园投资基金分别认购1000 万美元。 成立于2000年的毛戈平现旗下拥有两大品牌——旗舰品牌MAOGEPING于2000年推出，根据弗若 斯特沙利文的资料，其为中国第一个高端美妆品牌且在所有国货品牌 ...